Ie-Ming Shih, MD, PhD
Disclosures: Nothing to disclose - 07/07/2022

                  Ie-Ming Shih

CURRICULUM VITAE

 

The Johns Hopkins University School of Medicine

 

 

Ie-Ming Shih                                                                                                      Version: June 2, 2022

 

 

Dr. Ie-Ming Shih is the Richard W. TeLinde Distinguished Professor in the Department of Gynecology and Obstetrics (1) and is the director of this inter-departmental gynecologic disease research program at the Johns Hopkins Medical Institutions (2, 3). Dr. Shih also co-directs the Women’s Malignancy Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Born in Taiwan, Dr. Shih came to the US for his PhD study at the University of Pennsylvania before his clinical training at the Johns Hopkins Hospital. After completing residency, clinical fellowship and research fellowship at Hopkins, Dr. Shih became a faculty member there in 2000; his research focuses on exploring molecular landscapes and pathogenesis in different types of ovarian cancers, most notably their precursor lesions. Dr. Shih's work together with findings from other research groups has established that ovarian high-grade cancer originates from the fallopian tubes rather than the long-thought ovaries. These findings are transformative, and are leading to substantive changes in clinical practice including adopting opportunistic salpingectomy during hysterectomy. Dr. Shih has pioneered the genome-wide molecular genetic studies in endometriosis and show that the seemingly benign or “normal-appearing” endometriosis, which precedes many ovarian low-grade cancers, harbors cancer gene mutations and the epithelial but not stromal component within an endometriosis is clonal in origin. His recent data led him to propose a new hypothesis in the development of endometriosis that can explain its unique genotypes and phenotypes that have puzzled scientists and physicians for a long time better than any previously known theory. Dr. Shih’s new theory of endometriosis origin may create a new future research direction. Moreover, Dr. Shih (together with Dr. Robert Kurman) proposed a “dualistic” model for classifying ovarian cancer, which has become widely used (with more than 6,000 citations from his 5 main articles on this subject). Dr. Shih has also contributed to understanding the pathobiology of placental pathology and biology including the etiology of gestational trophoblastic neoplasms and his research serves as the foundation in assisting pathological diagnosis of this rare and unique group of trophoblastic diseases and placental pathology.

He is a sought after seminar speaker and lecturer around the world. He is also a devoted teacher, and has helped advance the career development of many young scientists and physicians in their pursuit of an academic career. He has served on several advisory boards including the NCI Ovarian Task Force of Gynecologic Cancer Steering Committee and the Ovarian Cancer Research Foundation, etc. He is a current or former editorial board member for numerous journals including Cancer Research, Journal of Pathology, American Journal of Pathology, and several others. He serves as an editorial/scientific board member for the World Health Organization (WHO) Classification of Female Genital Tumors. In the past two decades, his research has been continuously supported by the NIH/NCI, DoD, and several private foundation awards. He is one of the most highly funded principal investigators by the NIH in the fields of Pathology and Gynecology.  Dr. Shih has published extensively in the leading top-tier journals, including NEJM, Cancer Cell, PNAS, Science, Lancet Oncology, Nature, and Nature Medicine. He has an H-index of 112 and his research articles have been cited for more than 45,000 times. Dr. Shih is one of the top pathologists with most research citations in the field of gynecologic pathology in the world. He was the recipient of the Rosalind Franklin Prize for Excellence in Ovarian Cancer.

 

  1. https://professorships.jhu.edu/professorship/richard-w-telinde-distinguished-professorship-in-gynecological-pathology/
  2. www.hopkinsmedicine.org/gynecology_obstetrics/research/areas/telinde_lab.html
  3. www.gynecologycancer.org

DEMOGRAPHIC AND PERSONAL INFORMATION

 

Current Appointments

 

Richard W. TeLinde Distinguished Professor, Department of Gynecology and Obstetrics with secondary appointment in the Departments of Oncology and Pathology, Johns Hopkins Medical Institutions 

 

Co-Director, the Women’s Malignancy Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions 

 

Director, TeLinde Research Program for Gynecologic Diseases, Johns Hopkins Medical Institutions

                        

Personal Data

 

    Country of birth place: Dai-Chia Township, Tai-Chuan City, Taiwan

    Nationality/citizenship: 1) United States of America; 2) Taiwan

    Contact information:

Address: 1550 Orleans Street, CRB-2, RM 305, Baltimore, Maryland 21231

Office phone: 410-502-7774   

Fax: 410-502-7943

E-mail: ishih@jhmi.edu, shihie@yahoo.com

 

Forgien Appointement

 

   Adjunct Professor, Taipei Medical University, Taipei, Taiwan

 

EDUCATION AND TRAINING

 

Year                            Degree                                          Institution                            Discipline

1981-1988              M.D.                                          Taipei Medical University              Medicine

1989- 1993              Ph.D.                                          University of Pennsylvania              Biomedical Science (pathology)

1993-1994              Postdoctoral Fellow              The Wistar Institute                            Cancer Biology                                    

1994-1997              Resident                            Johns Hopkins Hospital              Pathology

1997-1998              Clinical Fellow                          Johns Hopkins Hospital              Gynecologic Pathology             

1998-2000              Research Fellow              Johns Hopkins Oncology Ctr.              Cancer Genetics 

                                                                         (w/ Dr. Bert Vogelstein)

 

PROFESSIONAL EXPERIENCE

 

       2000-2001              Instructor, Department of Pathology

              Johns Hopkins Medical Institutions, Baltimore, MD

 

       2001-2003              Assistant Professor, Department of Pathology

              Johns Hopkins Medical Institutions, Baltimore, MD

 

2003-2008                 Associate Professor, Departments of Gynecology and Obstetrics      Pathology, Oncology

              Johns Hopkins Medical Institutions, Baltimore, MD

 

2008-                                                    Professor, Departments of Gynecology/Obstetrics, Pathology, Oncology

              Johns Hopkins Medical Institutions, Baltimore, MD

 

2014-              Richard W. TeLinde Distinguished Professor (endowed Chair)

http://webapps.jhu.edu/namedprofessorships/professorshipdetail.cfm?professorshipID=220

              Department of Gynecology and Obstetrics

              Johns Hopkins University School of Medicine

 

Director of Johns Hopkins TeLinde Gynecologic Disease Research Program http://www.hopkinsmedicine.org/gynecology_obstetrics/research/areas/telinde_lab.htm

Department of Gynecology and Obstetrics

Johns Hopkins University School of Medicine

 

Co-director of the Women’s Malignancy Program,

Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, MD

 

 

RESEARCH ACTIVITIES              research website: www.gynecologycancer.org

 

Peer-Reviewed Research Articles

 

Dr. Shih’s publications can be found in NCBI My Bibliography at:

https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/47955017/

 

1.                 Shih IM, Chiang HS, Yang LL, Wang TL. Antimotility effects of Chinese herbal medicines on human sperm. J Formos Med Assoc, 89:466-9, 1990. PMID: 1977862

 

2.                 Valyi-Nagy I, Shih IM, Gyorfi T, Greenstein D, Elder DE, Herlyn M. Spontaneous and induced differentiation of cultured human melanoma cells.  Int J Cancer, 54:159-165, 1993. PMID: 8478142

 

3.                 Valyi-Nagy I, Hirka G, Jensen PJ, Shih IM, Juhasz I, Herlyn M. Undifferentiated keratinocytes control growth, morphology, and antigen expression of normal melanocytes through cell-cell contact.  Lab Invest, 69:152-159, 1993. PMID: 8350597

 

4.                 Juhasz I, Lazaurs GS, Murphy GF, Shih IM, Herlyn M. Development of pemphigus vulgaris-like lesions in severe combined immunodeficient (SCID) mice reconstituted with lymphocytes from patients.  J Clin Invest, 92:2401-2407, 1993. PMID: 8227357

 

5.                 Mancianti ML, Gyorfi T, Shih IM, Valyi-Nagy I, Levengood G, Menssen HD, Halpern A, Elder DE, Herlyn M. Growth regulation of cultured human nevus cells.  J Invest Dermatol, 100:281S-287S, 1993. PMID: 8440904

 

6.                 Shih IM, Herlyn M. The role of growth factors and their receptors in the development and progression of melanoma.  J Invest Dermatol, 100:196S-203S, 1993. PMID: 8381840

 

7.                 Shih IM, Herlyn M. Autocrine and paracrine roles of growth factors in human melanoma. In Vivo, 8:113-124, 1994. PMID: 7519892

 

8.                 Herlyn M, Shih IM. Interactions of melanocytes and melanoma cells with the microenvironment. Pigment Cell Res, 7:81-88, 1994. PMID: 8066024

 

9.                 Shih IM, Elder DE, Speicher D, Johnson JP, Herlyn M. Isolation and functional characterization of the A32 melanoma-associated antigens. Cancer Res, 54:2514-2520, 1994. PMID: 8162602

 

10.            Shih IM, Elder DE, Herlyn M. Regulation of Mel-CAM/MUC18 expression on melanocytes of different stages of tumor progression by normal keratinocytes. Am J Pathol, 145:837-845, 1994. PMID: 7943174

 

11.            Shih IM, Wang TL, Westra WH. Diagnostic and biologic implications of Mel-CAM expression in spindle cell neoplasms. Clin Cancer Res, 2:569-575, 1996. PMID: 9816205

 

12.            Shih IM, Kurman RJ. Expression of melanoma cell adhesion molecule in intermediate trophoblast. Lab Invest, 75: 377-388, 1996. (with cover illustration) PMID: 8804361

 

13.            Shih IM, Speicher D, Hsu MY, Levine E, Herlyn M. Melanoma cell-cell interactions are mediated through heterophilic Mel-CAM/ligand adhesion. Cancer Res, 57: 3835-3840, 1997. PMID: 9288796

 

14.            Shih IM, Hsu MY, Palazzo JP, Herlyn M. The cell-cell adhesion receptor Mel-CAM acts as a tumor suppressor in breast carcinoma. Am J Pathol, 151:745-751, 1997. PMID: 9284823

 

15.            Shih IM, Kurman RJ. New concepts in trophoblastic growth and differentiation with practical application for the diagnosis of gestational trophoblastic disease. Verh Dtsch Ges Path, 81: 266-272, 1997. PMID: 9474880

 

16.            Shih IM, Schnarr RL, Gearhart JD, Kurman RJ. Distribution of cells bearing the HNK-1 epitope in the human placenta. Placenta, 18:667-674, 1997. PMID: 9364602

 

17.            Hu PJ, Shih IM, Hutchins GM, Hellmann DB. Polyarteritis nodosa of the pericardium: antemortem diagnosis in a pericardiectomy specimen. J Rheumatol, 24:2042-2044, 1997. PMID: 9330952

 

18.            Shih IM, Kurman RJ. Ki-67 labeling index in the differential diagnosis of exaggerated placental site, placental site trophoblastic tumor, and choriocarcinoma: a double immunohistochemical staining technique using Ki-67 and Mel-CAM antibodies.

            Human Pathol, 29:27-33, 1998. (with cover illustration) PMID: 9445130

 

19.            Shih IM, Nesbit M, Herlyn M, Kurman RJ. A new Mel-CAM (CD146) specific monoclonal antibody, MN-4, on paraffin embedded tissue. Mod Pathol, 11:1098-1106, 1998. PMID: 9831208

 

20.            Shih IM, Kurman RJ. Epithelioid trophoblastic tumor --- a neoplasm distinct from choriocarcinoma and placental site trophoblastic tumor simulating carcinoma.  Am J Surg Pathol, 22:1393-1403, 1998. PMID: 9808132

 

21.            Shih IM, Wang T-L, Wu T-C, Kurman RJ, Gearhart JD. Expression of Mel-CAM in implantation site intermediate trophoblastic cell line, IST-1, limits its migration on uterine smooth muscle cells. J Cell Sci, 111: 2655-2664, 1998. PMID: 9701564

 

22.            Shih IM, Kurman RJ. Immunohistochemical localization of inhibin-alpha in the human placenta and gestational trophoblastic lesions. Int J Gynecol Pathol, 18:144-150, 1999. PMID: 10202672

 

23.            Huang C-C, Kashima ML, Chen H, Shih IM, Kurman RJ, Wu T-C. HPV in situ hybridization with catalyzed signal amplification and polymerase chain reaction in establishing cerebellar metastasis of a cervical carcinoma.  Human Pathol, 30:587-591, 1999.

 

24.            Shih IM. The role of CD146 (Mel-CAM) in biology and pathology. J Pathol, 189:4-11,1999. PMID: 10451481

 

25.            Suzuki N, Nakayama J, Shih IM, Daisuke Aoki, Nozawa S, Fukuda MN. Expression of trophinin, tastin and bystin by trophoblasts and endometrial cells in human placenta. Biol Reprod, 60: 621-627, 1999. PMID: 10026108

 

26.            Shih IM, Seidman JD, Kurman RJ. Placental site nodule and characterization of distinctive types of intermediate trophoblast. Hum Pathol, 30:687-694, 1999. (with cover illustration) PMID: 10374778

 

27.            Shih IM, Yu J, He TC, Vogelstein B, Kinzler KW. The beta-catenin binding domain of APC gene is sufficient for tumor suppression. Cancer Res, 60:1671-1676, 2000. PMID: 10822298

 

28.            Wang TL, Ling M, Shih IM, Pham T, Pai SI, Lu Z, Kurman RJ, Pardoll DM, Wu TC. Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity. Gene Therapy, 7:726-733, 2000.

 

29.            Shih IM, Torrance C, Sokoll L, Chan DW, Kinzler KW, Vogelstein B. Assessing tumors in living animals through measurement of urinary beta-human chorionic gonadotropin. Nature Med, 6:711-714, 2000. PMID: 10835692

 

30.            Koch MB, Shih IM, Weiss SW, Folpe AL. Microphthalmia transcription factor and melanoma cell adhesion molecule expression distinguish desmoplastic/spindle cell melanoma from morphologic mimics. Am J Surg Pathol, 25:58-64, 2001. PMID: 11145252

 

31.            Shih IM, Kurman RJ. Editorial: Placental site trophoblastic tumor- past as prologue. Gynecol Oncol, 82:413-414, 2001. PMID: 11520133

 

32.            Shih IM, Zhou W, Goodman S, Kinzler KW, Vogelstein B. Evidence that genetic instability occurs at an early stage of colorectal tumorigenesis. Cancer Res, 61:818-822, 2001. PMID: 11221861

 

33.            Shih IM, Wang TL, Traverso G, Romans K, Hamilton SR, Kinzler KW, Vogelstein B. Top-down morphogenesis of colorectal tumors. Proc Natl Acad Sci USA, 98:2640-2645, 2001. PMID: 11226292

 

34.            Shih IM, Yan H, Speyrer D, Shmookler BM, Sugarbaker PH, Ronnett BM. Molecular genetic analysis of appendiceal mucinous adenomas in identical twins, including one with pseudomyxoma peritonei. Am J Surg Pathol, 25:1095-1099, 2001. PMID: 11474297

 

35.            Shih IM, Kurman RJ. The pathology of intermediate trophoblastic tumors and tumor-like lesions. Int J Gynecol Pathol, 20:31-47, 2001. PMID: 11192071

 

36.            Shih IM, Kurman RJ. Molecular basis of gestational trophoblastic diseases. Curr Mol Medicine, 2:1-12, 2002. PMID: 11898845

 

37.            Singer G, Kurman RJ, Chang H-W, Cho SKR, Shih IM. Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol, 160:1223-1228, 2002. PMID: 11943707

 

38.            Gerstein AV, Almeida TA, Ahao G, Chess E, Shih IM, Buhler K, Pienta K, Rubin MA, Vellella R, Papadopoulos N. APC/CTNNB1 (beta-catenin) pathway alterations in human prostate cancers. Genes, Chromosomes & Cancer, 34:9-16, 2002. PMID: 11921277

 

39.            Singer G, Kurman RJ, McMaster MT, Shih IM. HLA-G immunoreactivity is specific for intermediate trophoblast in gestational trophoblastic disease and can serve as a useful marker in differential diagnosis. Am J Surg Pathol, 26:914-920, 2002. PMID: 12131159

 

40.            Oldt R J, Kurman RJ, Shih IM. Molecular genetic analysis of placental site trophoblastic tumors and epithelioid trophoblastic tumors confirms their trophoblastic origin. Am J Pathol, 161:1033-1038, 2002. PMID: 12213732

 

41.            Hickman TN, Shih IM, Zacur HA, Kurman RJ, Diener-West M, Gearhart JD. Decreased progesterone receptor expression in the intermediate trophoblastic cells of spontaneous abortions. Fertil Steril, 77:1001-1005, 2002. PMID: 12009358

 

42.            Chang H-W, Ali SZ, Cho SR, Kurman RJ, Shih IM. Detection of allelic imbalance in ascitic supernatant by digital SNP analysis. Clin Cancer Res, 8:2580-2585, 2002. PMID: 12171887

 

43.            Chang H-W, Yen C-Y, Liu S-Y, Singer G, Shih IM. Genotype analysis using human hair shaft. Cancer Epidemiol Biomark Prev, 11:925-929, 2002. PMID: 12223440

 

44.            Chang H-W, Singer G, Cho SR, Sokoll L, Montz F, Roden R, Zhang Z, Chan DW, Kurman RJ, Shih IM. Assessment of plasma DNA levels, allelic imbalance and CA 125 as diagnostic tests for cancer. J Natl Can Inst, 94:1697-1703, 2002. PMID: 12441325

 

45.            Nowak MA, Komarova NL, Sengupta A, Jallepalli PV, Shih IM, Vogelstein B, Lengauer C. The role of chromosomal instability in tumor initiation. Proc Natl Acad Sci USA, 99:16226-16231, 2002. PMID: 12446840

 

46.            Shih IM, Hsu M-Y, Oldt RJ III, Herlyn M, Gearhart JD, Kurman RJ. The role of E-cadherin in the motility and invasion of implantation site intermediate trophoblast. Placenta, 23:706-715, 2002. PMID: 12398810

 

47.            Rai AJ, Zhang Z, Rosenzweig J, Shih IM, Pham T, Fung ET, Sokoll LJ, Chan DW. Proteomic approaches to tumor marker discovery- identification of biomarkers for ovarian cancer. Arch Pathol Lab Med, 126:1518-1526, 2002. PMID: 12456215

 

48.            Fregnani ER, Pires FR, Quezada RD, Shih IM, Vargas PA, de Almeida OP. Calcifying odontogenic cyst: clinicopatholgoical features and immunohistochemical profile of 10 cases. J Oral Pathol Med, 32:163-170, 2003. PMID: 12581386

 

49.            Singer G, Shih IM, Truskinovsky A, Umudum H, Kurman RJ. Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: Invasive MPSC (a low-grade tumor) and conventional serous carcinoma (a high-grade tumor). Int J Gynecol Pathol, 22:37-41, 2003. PMID: 12496696

 

50.            Singer G, Oldt 3rd R, Cohen Y, Wang B, Sidransky D, Kurman RJ, Shih IM. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma.  J Natl Can Inst, 95:484-486, 2003. PMID: 12644542

 

51.            Pires FR, Shih IM, Perez DE, Almeida OP, Kowalski LP. Mel-CAM (CD146) expression in parotid mucoepidermoid carcinoma. Oral Oncol 39:277-281, 2003. PMID: 12618200

 

52.            Buckhaults P, Zhang Z, Chen Y-C, Wang T-L, St. Croix B, Saha S, Bardelli A, Morin PJ, Polyak K, Hruban RH, Velculescu VE, Shih IM. Identifying tumor origin using a gene expression based classification map. Cancer Res, 63:4144-4149, 2003 (with cover illustration). PMID: 12874019

 

53.            Wang BG, Huang H-Y, Chen Y-C, Bristow RE, Kassauei K, Cheng C-C, Roden R, Sokoll LJ, Chan DW, Shih IM. Increased plasma DNA integrity in cancer patients. Cancer Res, 63:3966-3968, 2003. PMID: 12873992

 

54.            Singer G, Rebmann V, Chen Y-C, Liu H-T, Ali SZ, Reinsberg J, McMaster MT, Pfeiffer K, Chan DW, Wardelmann E, Grosse-Wilde H, Cheng CC, Kurman RJ, Shih IM. HLA-G is a potential tumor marker in malignant effusion. Clin Cancer Res, 9: 4460-4466, 2003. PMID: 14555519

 

55.            Wang TL, Diaz L, Roman K. Bardelli A, Saha S, Parmigiani G, Choti M, Shih IM, Iacobuzio-Donahue C, Kinzler KW, Vogelstein B, Lengauer C, Velculescu V. Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-FU in metastatic colorectal cancer patients. Proc Natl Acad Sci USA, 101:3089-3094, 2004. PMID: 14970324

 

56.            Berman DM, Shih IM, Burke L-A, Veenstra TD, Zhao Y, Contrads TP, Kwon SW, Hoang V, Yu L-R, Zhou M, Kurman RJ, Petricoin EF, Liotta LA. Profiling the activity of G proteins in patient-derived tissues by rapid affinity-capture of signal transduction protein (GRASP). Proteomics, 4:812-818, 2004. PMID: 14997501

 

57.            Shih IM and Kurman RJ. p63 expression is useful in the distinction of epithelioid trophoblastic tumors and placental site trophoblastic tumor by profiling trophoblastic subpopulations. Am J Surg Pathol, 28:1177-1183, 2004. PMID: 15316317

 

58.            Cheng EJ, Kurman RJ, Wang M, Oldt III R, Wang BG, Berman DM, Shih IM.  Molecular genetic analysis of ovarian serous cystadenoma. Lab Invest, 84:778-784, 2004.  PMID: 15077125

 

59.            Pohl G and Shih IM. Principle and applications of digital PCR. Expert Rev Mol Diagn, 4:89-95, 2004. PMID: 14711348

 

60.            Shih IM and Kurman RJ. Ovarian tumorigenesis - a proposed model based on morphological and molecular genetic analysis. Am J Pathol, 164: 1511-1518, 2004. PMID: 15111296

 

61.            Hsu C-Y, Bristow R, Cha MS, Wang BG, Ho C-L, Kurman RJ, Wang TL, Shih IM.

            Characterization of Active Mitogen-activated Protein Kinase in Ovarian Serous Carcinomas. Clin Cancer Res, 10:6432-6436, 2004. PMID: 15475429

 

62.            Ho C-L, Kurman RJ, Dehari R, Wang T-L, Shih IM. Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. Cancer Res, 64:6915-6918, 2004. PMID: 15466181

 

63.            Garg R, Russell JJ, Shih, IM, Bristow RE. Have you ruled out a placental site nodule? Contempory Ob/Gyn, 49:18-20, 2004.

 

64.            Davidson B, Elstrand MV, McMaster MT, Berner A, Kurman RJ, Risberg B, Trope CG, Shih IM. HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma. Gyn Oncol, 96:42-47, 2005. PMID: 15589578

 

65.            Singer G, Stohr R, Cope L, Dehari R, Hartmann A, Cao D-F, Wang TL, Kurman RJ, Shih IM. Patterns of p53 mutations separate ovarian serous borderline tumors, low and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis. Am J Surg Pathol, 29:218-224, 2005. PMID: 15644779

 

66.            Chang HW, Shih IM. Digital single-nucleotide polymorphism analysis for allelic imbalance. Methods Mol Med, 103: 137-141, 2005. PMID: 15542903

 

67.            Chen Y-C, Pohl G, Wang TL, Morin PJ, Risberg B, Christesen GB, Yu A, Davidson B, Shih IM. Apolipoprotein E is required for cell proliferation and survival in ovarian cancer. Cancer Res, 65:331-337, 2005. PMID: 15665311

 

68.            Hansel DE, Rahman A, Wilentz RE, Shih IM, McMaster MT, Yeo CJ, Maitra A. HLA-G upregulation in pre-malignant and malignant lesions of the gastrointestinal tract. Int J Gastrointestinal Cancer, 35:15-24, 2005. PMID: 15722570

 

69.            Pohl G, Ho C-L, Kurman RJ, Bristow R, Wang T-L, Shih IM. Inactivation of the MAPK pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations.  Cancer Res, 65:1994-2000, 2005. PMID: 15753399

 

70.            Lai TH, Shih IM, Vlahos N, Ho CL, Wallach E, Zhao Y. Differential expression of L-selectin ligand in the endometrium during the menstrual cycle. Fertility and Sterility, 83/4S: 1297-1302, 2005. PMID: 15831305

 

71.            Köbel M, Pohl G, Schmitt WD., Hauptmann S, Wang T-L, Shih IM. Activation of mitogen activated protein kinase is required for migration and invasion of placental site trophoblastic tumor. Am J Pathol, 167:879-885, 2005. PMID: 16127165

 

72.            Shih IM and Wang TL. Apply innovative technologies to explore cancer genome.

            Curr Opin Oncol, 17:33-38, 2005. PMID: 15608510

 

73.            Shih IM and Kurman RJ. Molecular pathogenesis of ovarian borderline tumors- new insights and old challenges. Clin Cancer Res, 11:7273-7279, 2005. PMID: 16243797

 

74.            Chen YC, Davidson B, Cheng CC, Maitra A, Giuntoli RL 2nd, Hruban RH, Wang T-L, Shih IM.  Identification and characterization of membralin, a novel tumor-associated gene, in ovarian carcinoma. Biochem Biophys Acta, 1730:96-102, 2005.  PMID: 16084606

 

75.            Hsu C-Y, Kurman RJ, Vang R, Wang T-L, Baak J, Shih IM. Nuclear size distinguishes low-grade from high-grade ovarian serous carcinoma and predicts outcome. Human Pathol, 36:1049-1054, 2005. PMID: 16226103

 

76.            Cooper T.K. Shih IM, Gabrielson KL. Uterine epithelioid trophoblastic tumor in a red-tailed Guenon (Cercopithecus ascanius). J Comp Path, 133:218-222, 2005. PMID: 16026797

 

77.            Kurman RJ, Seidman JD, Shih IM. Expert Opinion: Serous borderline tumors of the ovary, classifications, concepts and conundrums. Histopathol, 47:310-318, 2005. PMID: 16115232

 

78.            Shih IM, Sheu J, Yu CH, Santillan A, Yen MJ, Nakayama K, Bristow RE, Vang R, Parmigiani G, Kurman RJ, Trope CG, Davidson B and Wang T-L.  Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma. Proc Natl Acad Sci USA, 102:14004-14009, 2005. PMID: 16172393

 

79.            Yen JM, Hsu C-Y, Mao T-L, Wu, TC, Roden R, Wang T-L, Shih IM. Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma. Clin Cancer Res, 12:827-831, 2006. PMID: 16467095

 

80.            Song J, Yang W, Shih IM, Zhang Z, Bai J. Identification of BCOX1, a novel gene overexpressed in breast cancer. Biochem Biophys Acta, 1760:62-69, 2006. PMID: 16289875

 

81.            Lai T-H, Zhao Y, Shih IM, Ho C-L, Bankowski B, Vlahos N. Expression of L-selectin ligands in human endometrium during the implantation window after controlled ovarian stimulation for oocyte donation. Fertil Steril, 85:761-763, 2006. PMID: 16500358

 

82.            Kleinberg L, Flørenes V, Skrede M, Dong, Hiep Phuc, Nielsen, Søren, McMaster M, Nesland, J, Shih IM, Davidson B.  Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma.  Virchows Archiv, 449:31-39, 2006. PMID: 16541284

 

83.            Mao T-L, Seidman JD, Kurman RJ, Shih IM. Cyclin E and p16 immunoreactivity in epithelioid trophoblastic tumor-an aid in differential diagnosis. Am J Surg Pathol, 30:1105-1110, 2006. PMID: 16931955

 

84.            Bazzaro M, Lee MK, Zoso A, Stirling WLH, Santillan A, Shih IM, Roden RBS. Ubiquitin-proteosome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis. Cancer Res, 66:3754-3763, 2006. PMID: 16585202

 

85.            Yeh H-C, Ho Y-P, Shih IM, Wang TH. Homogeneous point mutation detection by quantum dot-mediated tow-color fluorescence coincidence analysis. Nuclei Acid Res, 34:e35, 2006. PMID: 16517937

 

86.            Nakayama K, Nakayama N. Kurman RJ, Cope L, Pohl G, Samuels Y, Velculescu VE, Wang TL, Shih IM. Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms. Cancer Biol Therapy, 5:779-785, 2006. PMID: 16721043

 

87.            Nakayama K, Nakayama N, Davidson B, Katabuchi H, Kurman RJ, Velculescu VE, Shih IM, Wang TL. Homozygous deletion of MKK4 in ovarian serous carcinoma. Cancer Biol Therapy, 6:630-634, 2006. PMID: 16627982

 

88.            Park, JT, Li M, Nakayama K, Mao T-L, Davidson B, Zheng Z, Kurman RJ, Eberhart CG, Shih IM, Wang TL. Notch-3 gene amplification in ovarian cancer. Cancer Res, 66:6312-6318, 2006. PMID: 16778208

 

89.            Mao T-L, Hsu C-Y, Yen MJ, Gilks B, Sheu JC, Gabrielson E, Vang R, Cope L, Kurman RJ, Wang TL, Shih IM. Expression of Rsf-1, a chromatin-remodeling gene, in ovarian and breast carcinoma. Human Pathol, 37:1169-1175, 2006. PMID: 16938522

 

90.            Davidson B, Trope G, Wang T-L, Shih IM.  Expression of the chromatin remodeling factor, Rsf-1, in effusions is a novel predictor of poor survival in ovarian carcinoma. Gyn Oncol, 103:814-819, 2006. PMID: 16844205

 

91.            Staebler A, Karberg B, Behm J, Kuhlmann P, Neubert U, Schmidt H, Korsching E, Burger H, Lelle R, Kiesel L, Bocker W, Shih  IM, Buchweitz O. Chromosomal losses of regions on 5q and lack of high-level amplification at 8q24 are associated with favorable prognosis for ovarian serous carcinoma. Gene Chromosome and Cancer, 45:905-917, 2006. PMID: 16845658

 

92.            Vlahos NF, Lipari CW, Bankowski B, Lai TH, King JA, Shih IM, Fragakis K, Zhao Y. Effect of luteal-phase support on endometrial L-selectin ligand expression following recombinant follicle-stimulating hormone and ganirelix acetate for in vitro fertilization. J Clin Endocrinol Metab 91:4043-4049, 2006 PMID: 20132413

 

93.            Davidson B, Kleinberg L, Forences VA, Zhang Z, Wang TL, Shih IM. Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from diffuse peritoneal malignant mesothelioma. Clin Cancer Res, 12:5944-5950, 2006.

 

94.            Nakayama K, Nakayama N, Davidson B, Sheu J, Natini Jinawath, Santillan A, Salani R, Bristow RE, Morin PJ, Kurman RJ, Wang TL, Shih IM. A BTB/POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survival. Proc Natl Acad Sci USA, 103:18739-18744, 2006. PMID: 17509990

 

95.            Klleinberg L, Holth A, Fridman E, Schwartz I, Shih IM, Davidson B. The diagnostic role of claudins in serous effusions. Am J Clin Pathol, 127:928-937, 2007

 

96.            Salani R, Neuberger I, Kurman RJ, Bristow R, Chang HW, Wang TL, Shih IM. Expression of extracellular matrix proteins in ovarian serous tumors. Int J Gynecol Pathol, 26:141-146, 2007. PMID: 17413980

 

97.            Lai TH, King JA, Shih IM, Vlahos NF, Zhao Y. Immunological localization of syndecan-1 in human endometrium throughout the menstrual cycle. Fertil Steril, 87:121-126, 2007.  PMID: 17113089

 

98.            Reiko D, Kurman RJ, Logani S, Shih IM. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma- a morphologic and molecular genetic analysis. Am J Surg Pathol, 31:1007-1012, 2007. PMID: 17592266

 

99.            Chu D, Shih IM, Knechevich M, Sheth S. Uterine epithelioid trophoblastic tumor in an African green monkey (Chlorocebus aethiops sabaeus). J Am Assoc Lab Animal sci. 46:92-96, 2007. PMID: 17343360

 

100.        Shih IM, Wang TL. Notch signaling, gamma secretase inhibitors and cancer therapy. Cancer Res, 67:1879-1882, 2007. PMID: 17332312

 

101.        Shih IM. Applications of HLA-G expression in the diagnosis of human cancer. Hum Immunol, 68:272-276, 2007. PMID: 17400063

 

102.        Shih IM. Trophogram, an immunohistochemistry-based algorithmic approach, in the differential diagnosis of trophoblastic tumors and tumor-like lesions. Ann Diag Pathol, 11:228-234, 2007. PMID: 17498600

 

103.        Shih IM. Gestational trophoblastic neoplasia- pathogenesis and potential therapeutic targets. Lancet Oncology, 8:642-650, 2007. PMID: 17613426

 

104.        Sheu J, Shih IM. The clinical and biological significance of HLA-G expression in ovarian cancer. Seminar Cancer Biology, 17:436-443, 2007. PMID: 17681474

 

105.        Santillan A, Kim YW, Zahurak ML, Gardner GJ, Giuntoli II RL, Shih IM, Bristow RE. Differences of chemoresistance assay between invasive micropapillary/low-grade serous ovarian carcinoma and high-grade serous ovarian carcinoma. Int J Gyn Cancer, 17:601-606, 2007. PMID: 17504374

 

106.        Shih IM, Salani R, Fiegl M, Wang TL, Soosaipillai A, Marth C, Muller-Holzner E, Gastl G, Zhang A, Diamandis EP. Ovarian cancer specific kallikrein profile in effusions. Gyn Oncol, 105:501-507, 2007. (PMID: 17303231)

 

107.        Nakayama K, Nakayama N, Jinawath N, Salani R, Kurman RJ, Shih IM, Wang TL. Amplicon profiles in ovarian serous carcinomas. Int J Cancer, 120: 2613-2617, 2007. PMID: 17351921

 

108.        Davidson B, Berner A, Trope CG, Wang TL, Shih IM. Expression and clinical role of the BTB/POZ protein NAC-1 in ovarian carcinoma effusions. Hum Pathol, 38:1030-1036, 2007. PMID: 17413980

 

109.        Cheng WF, Hung CF, Chai CY, Chen CA, Lee CN, Su YN, Tseng WY, Hsieh CY, Shih IM, Wang TL, Wu. Generation and characterization of an ascitogenic mesothelin-expressing tumor model. Cancer, 110: 420-431, 2007. PMID: 17559144

 

110.        Nakayama K, Nakayama N, Wang TL, Shih IM. NAC-1 controls cell growth and survival by repressing transcription of Gadd45GIP1, a candidate tumor suppressor. Cancer Res, 67: 8058-8064, 2007. PMID: 17804717

 

111.        Davidson B, Skrede M, Silins I, Shih IM, Trope CG, Flørenes VA.  Low molecular weight cyclin E forms differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma. Cancer, 110:1264-1271, 2007. PMID: 17647260

 

112.        Salani R, Davidson B, Fiegl M, Huang HY, Marth C, Muller-Holzner E, Gastl G, Hsiao JC, Lin HS, Wang TL, Lin BL, Shih IM. Measurement of cyclin E genomic copy number and strand length in cell-free DNA distinguishes malignant versus benign effusions. Clin Cancer Res, 13:5805-5809, 2007. PMID: 17908972

 

113.        Song J, Shih IM, Salani R, Chan DW, Zhang Z. Annexin XI is associated with cisplatin resistance and related to tumor recurrence in ovarian cancer patients. Clin Cancer Res, 13:6842-6849, 2007. PMID: 17982121

 

114.        Davidson B, Baekelandt M, Shih IM. Mucin4 is upregulated in ovarian carcinoma effusions and differentiates carcinoma cells from mesothelial cells. Diagn Cytopathol, 35:756-760, 2007. PMID: 18008338

 

115.        Mao TL, Kurman RJ, Huang CC, Lin MC, Shih IM. Immunohistochemistry of choriocarcinoma: an aid in differential diagnosis and in elucidating pathogenesis. Am J Surg Pathol, 31:1726-1732, 2007. PMID: 18059230

 

116.        Bazzaro M, Santillan A, Lin Z, Tang T, Lee MK, Bristow RE, Shih IM, Roden RB. Myosin II co-chaperone general cell UNC-45 overexpression is associated with ovarian cancer, rapid proliferation, and motility. Am J Pathol, 171:1640-1649, 2007. PMID: 17872978

 

117.        Mao TL, Kurman RJ, Jeng YM, Huang W, Shih IM. HSD3B1 as a novel trophoblast-associated marker that assists in the differential diagnosis of trophoblastic tumors and tumor-like lesions. Am J Surg Pathol, 32:236-242, 2008. PMID: 18223326

 

118.        Salani, R, Kurman RJ, Giuntoli R, Gardner G, Bristow R, Wang TL, Shih IM. Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a much higher mutation rate than previously reported and does not correlate with drug resistance. Int J Gyn Cancer, 18:487-491, 2008. (PMID: 17692090)

 

119.        Davidson B, Wang TL, Shih IM, Berner A. Expression of the chromatin remodeling factor Rsf-1 is down-regulated in breast carcinoma effusions. Hum Pathol, 39:616-622, 2008. PMID: 18289639

 

120.        Brown L, Kalloger SE, Miller MA, Shih IM, McKinney SE, Santos JL, Swenerton K, Spellman PT, Gray J, Gilks CB, Huntsman DG. Amplification of 11q13 in ovarian carcinoma. Genes, Chromosome and Cancer, 47:481-489, 2008. PMID: 18314909

 

121.        Kurman RJ and Shih IM. Pathogenesis of ovarian cancer- Lessons from morphology and molecular biology and their clinical implications. Int J Gyn Pathol, 27:151-160, 2008. PMID: 18317228

 

122.        Kurman RJ, Visvanathan K, Roden R, Wu TC, Shih IM. Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am J Obst Gyn, 198:351-356, 2008. (PMID: 18395030)

 

123.        Davidson B, Shih IM, Wang TL. Different clinical roles for p21-activated kinase-1 in primary and recurrent ovarian carcinoma. Hum Pathol, 39:1630-1636, 2008. PMID: 18656238

 

124.        Sheu J, Choi JH, Lin A, Yyldyz I, Tsai F-J, Shaul Y, Wang TL, Shih IM. The roles of human sucrose nonfermenting protein 2 homologue in the tumor-promoting functions of Rsf-1. Cancer Res, 68:4050-4057, 2008.  PMID: 18519663

 

125.        Dahiya N, Sherman-Baust CA, Wang T-L, Davidson B, Shih IM, Zhang Y, Wood W III, Becker KG, Morin PJ. MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS ONE, 3:e2436, 2008. PMID: 18560586

 

126.        Shih IM, Kuo KT. The power of the every youth- Nanog expression in gestational choriocarcinoma. Am J Pathol, 173:911-914, 2008. PMID: 18755845

127.        Vang R, Shih IM, Salani R, Sugar E, Ayhan A, Kurman RJ. Subdividing ovarian and peritoneal serous carcinoma into moderately- and poorly-differentiated does not have biologic validity based on molecular genetic and in vitro drug resistance data. Am J Surg Pathol, 32:1667-1674, 2008. PMID: 18769340

 

128.        Choi J-H, Park JT, Davidson B, Morin PJ, Shih IM, Wang TL. Jagged-1 and Notch3 juxtacrine loop regulates ovarian tumor growth and adhesion. Cancer Res, 68:5716-5723, 2008. PMID: 18632624

 

129.        Chen L, Xuan J, Wang C, Shih IM, Wang TL, Zhang Z, Clarke R, Hoffman E, Wang Y. Biomarker identification by knowledge-driven multi-level ICA and motif analysis. Intl J. Data Mining and Bioinformatics, 3(4):365-81 2009. PMID: 20052902.

 

130.        Tsai HW, Lin CP, Chou CY, Li CF, Chow NH, Shih IM, Ho CL. Placental site nodule transformed into a malignant epithelioid trophoblastic tumor with pelvic lymph node and lung metastasis. Histopathol, 53:601-604, 2008 PMID: 18983471

 

131.        Yemelyanova A, Mao TL, Nakayama N, Shih IM, Kurman RJ.  Macropapillary serous carcinoma of the ovary. A distinctive type of low-grade serous carcinoma. Am J Surg Pathol, 32:1800-1806, 2008. PMID: 18779727

 

132.        Park J. Shih IM, Wang TL.  Identification of Pbx1, a potential oncogene, as a Notch3 target gene in ovarian cancer. Cancer Res, 68:8852-60, 2008. PMID: 18974129

 

133.        Chen LL, Xuan J, Wang C, Shih IM, Wang Y, Zhang Z, Hoffman E, and Clarke R. Knowledge-guided multi-scale independent component analysis for biomarker identification. BMC Bioinformatics, 9:416, 2008. PMID: 18837990

 

134.        Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brunner N, Chan DW, Babaian R, Bast Jr R, Dowell B, Esteva FJ, Haglund C, Harbeck N, Hayes DF, Holten-Andersen M, Klee GG, Lamerz R, Looijenga LH, Molina R, Nielsen HJ, Rittenhouse H, Semjonow A, Shih IM, Sibley P, Soletormos G, Stephan C, Sokoll L, Hoffman BR, Diamandis EP. National academy of clinical biochemistry laboratory medicine practice guideline for use of tumor markers in testicular, prostate, colorectal, breast and ovarian cancers. Clin Chem, 54:12 e11-e79, 2008. PMID: 19042984

 

135.          Cho K, Shih IM. Ovarian cancer. Annual Review Pathol, 4:287-313, 2009. PMID: 18842102

 

136.        Choi JH, Sheu J, Guan B, Jinawath N, Markowski P, Wang TL, Shih IM. Functional analysis of 11q13.5 amplicon identifies Rsf-1 (HBXAP) as a gene involved in paclitaxel resistance in ovarian cancer. Cancer Res, 69:1407-1415, 2009. PMID: 19190325

 

137.        Sheu J, Hua CH, Wan L, Lin YJ, Lai MT, Tseng HC, Jinawath N, Tsai MH, Chang NW, Lin CF, Lin CC, Hsieh LJ, Wang TL, Shih IM, Tsai FJ. Functional genomic analysis identified EGFR activation as the most common genetic event in oral squamous cell carcinoma. Cancer Res, 69:2568-2576, 2009. PMID: 19276369

 

138.        Veras E, Mao TL, Ayhan A, Ueda S, Lai H, Shih IM, Kurman RJ. Cystic and adenofibromatous clear cell carcinomas of the ovary, distinctive tumors that differ in their pathogenesis and behavior: A clinicopathologic analysis of 122 cases. Am J Surg Pathol, 33:844-853, 2009. PMID: 19342944

 

139.        Kobel M, Xu H, Bourne PA, Spaulding BO, Shih IM, Mao TL, Soslow R, Ewanowich C, Kalloger SE, Mehl E, Lee CH, Huntsman D, Gilks CB. IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype. Modern Pathol, 22:469-475, 2009. PMID: 19136932

 

140.        Kuo KT, Mao TL, Jones S, Veras E, Ayhan A, Wang TL, Glas R, Slamon D, Velculescu VE, Kurman RJ, Shih IM. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol, 174:1597-1601, 2009. PMID: 19342944

 

141.        Ayhan A, Kurman RJ, Vang R, Logani S, Seidman, Shih IM. Defining the cut-point between low- and high-grade ovarian serous carcinomas: A clinicopathologic and molecular genetic analysis. Am J Surg Pathol, 33:1220, 2009. PMID: 19461510

 

142.        Kuo KT, Guan B, Feng Y, Mao TL, Chen X, Jinawath N, Wang Y, Kurman RJ, Shih IM, Wang TL. Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas. Cancer Res, 69:4036-4042, 2009. PMID: 19383911

 

143.        Jinawath N. Nakayama K, Yap K, Thiaville M, Wang TL, Shih IM. NAC-1, a potential stem cell pluripotency factor, contributes to paclitaxel resistance in ovarian cancer through inactivating Gadd45 pathway. Oncogene, 28: 1941-1948, 2009. PMID: 19305429

 

144.        Lotan TL, Ye H, Melamed J, Wu XR, Shih IM, Epstein JI. Immunohistochemical panel to identify the primary site of invasive micropapillary Carcinoma. Am J Surg Pathol, 33:1037-1041, 2009. (PMID: 19238079)

 

145.        Song J, Shih IM, Chan DW, Zhang Z. Suppression of annexin A11 in ovarian cancer: implications in chemoresistance, Neoplasia, 11:605-614, 2009. PMID: 19484149

 

146.        Mao TL, Shih IM. Advances in the diagnosis of gestational trophoblastic tumor and tumor-like lesions (review). Expert Opin Med Diagn, 3:371-380, 2009.

 

147.        Yuan Y, Nymoen DA, Dong HP, Bjorang O, Shih IM, Low PS, Trope CG, Davidson B. Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous effusions. Hum Pathol, 40:1453-1460, 2009. PMID: 19454358

 

148.        Tsai-Turton M, Santillan A, Lu D, Bristow RE, Chan KC, Shih IM, Roden RB. p53 autoantibodies, cytokine levels and ovarian carcinogenesis. Gynecol Oncol, 114:12-17, 2009. PMID: 19398128

 

149.        Vang R, Shih IM, Kurman RJ. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anatomic Pathol, 16:267-282, 2009. PMID: 19700937

 

150.        Yemelyanova A, Ji H, Shih IM, Wang TL, Wu LS, Ronnett BM. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases. Am J Surg Pathol, 33:1504-1514, 2009 PMID: 19623034

 

151.        Tian Y, Tan A-C, Sun X, Olso MT, Xie Z, Jinawath N, Chan DW, Shih IM, Zhang Z, and Zhang H. Quantitative proteomic analysis of ovarian cancer cells identified mitochondrial proteins associated with paclitaxel resistance.  Proteomics Clin Appli, 3:1288-1295, 2009.

 

152.        Allan RW, Algood CB, Shih IM. Metastatic epithelioid trophoblastic tumor in a male patient with mixed germ cell tumor of the testis. Am J Surg Pathol, 33:19021905, 2009. PMID: 19898219

 

153.        Ueda S, Mao TL, Kuhajda F, Giuntoli RL 2nd, Bristow R, Kurman RJ, Shih IM. Gestational trophoblastic neoplasms express fatty acid synthase which may be a therapeutic target using its inhibitor, C93. Am J Pathol, 175:2618-2624, 2009. PMID: 19893031

 

154.        Shih IM and Davidson B. Pathogenesis of ovarian cancer- clues from selected overexpressed genes. Future Oncol, 5:1641-1657, 2009. PMID: 20001801

 

155.        Chen L, Xuan J, Wang C, Wang Y, Shih IM, Wang TL, Zhang Z, Clarke R, Hoffman EP. Biomarker identification by knowledge-driven multilevel ICA and motif analysis. Int J Data Min Bioinform, 3:365-81, 2009. PMID: 20052902

 

156.        Feng Y, Yu G, Wang TL, Shih IM, Wang Y. Analyzing DNA copy number changes using fused margin regression. Int J Functional Informatics and Personalised Medicine, 3:3-15, 2010.

 

157.        Kurman RJ, Shih IM. The origin and pathogenesis of epithelial ovarian cancer- a proposed unifying theory. Am J Surg Pathol, 34:433-443, 2010. PMID: 20154587

 

158.        Sheu J, Shih IM. HLA-G and immune evasion in cancer cells. J Formos Med Assoc, 109:248-257, 2010. PMID: 20434034

 

159.        Yap KL, Hafez MJ, Mao T-L, Kurman RJ, Murphy KM, Shih IM. Lack of a Y-chromosomal complement in the majority of gestational trophoblastic neoplasms. J Oncol, 2010:364508, 2010.  PMID: 20182630

 

160.        Gross A, Kurman RJ, Vang R, Shih IM, Visvanathan K. Precursor lesions of high-grade serous ovarian carcinoma: Morphological and molecular characteristics. J Oncol, 2010:126295, 2010. PMID: 20445756. 

 

161.        Sehdev AS, Kurman RJ, Kuhn E, Shih IM. Serous tubal intraepithelial carcinoma upregulates markers associated with high-grade serous carcinomas including Rsf-1 (HBXAP), cyclin E and fatty acid synthase. Mod Pathol, 23:844-855, 2010. PMID: 20228782

 

162.        Ueda SM, Yap KL, Davidson B, Tian Y, Murthy V, Wang, TL, Visvanathan K, Kuhajda FP, Bristow RE, Zhang H, Shih IM. Expression of fatty acid synthase depends on NAC1 and is associated with recurrent ovarian serous carcinomas. J Oncol, 2010:285191, 2010.  PMID: 20508725

 

163.        Shih IM. Ovarian serous low-malignant-potential (borderline) tumor- does “micropapillary” matter? (Editorial). Gyn Oncol, 117:1-3, 2010. PMID: 20298906

 

164.        Kuo KT, Mao TL, Chen X, Feng Y, Nakayama K, Wang Y, Glas R, Ma J, Kurman RJ, Shih IM, Wang TL.  DNA copy number profiles in affinity-purified ovarian clear cell carcinoma. Clin Cancer Res, 16:1997-2008, 2010.  PMID: 20233889

 

165.        Kuhn E, Meeker A, Wang TL, Sehdev AS, Kurman RJ, Shih IM. Shortened telomeres in serous tubal intraepithelial carcinoma: an early event in ovarian high-grade serous carcinogenesis. Am J Surg Pathol, 34:829-836, 2010. PMID: 20431479

 

166.        Sun L, Kong B, Sheng X, Sheu JC, Shih IM. Dendritic cells transduced with Rsf-1/HBXAP gene generate specific cytotoxic T lymphocytes against ovarian cancer in vitro. Biochem Biophys Res Commun., 394:633-638, 2010. PMID: 20226169

 

167.        Jinawath N, Vasoontara C, Jinawath A, Fang X, Zhao K, Yap, KL, Guo T, Lee CS, Wang W, Balgley BM, Davidson B, Wang, TL, Shih IM. Oncoproteomic analysis reveals co-upregulation of RELA and STAT5 in carboplatin resistant ovarian carcinoma.  PLoS ONE, 5:e11198, 2010. PMID: 20585448

 

168.        Liu K, Brock M, Shih IM, Wang TH, Decoding circulating nucleic acids in human serum using microfluidic single molecule spectroscopy. J Am Chem Soc, 132:5793-5798, 2010. PMID: 20364832

 

169.        Yu G, Miller DJ, Xuan J, Hoffman EP, Clarke R, Davidson B, Shih IM, Wang Y. Matched gene selection and committee classifier for molecular classification of heterogeneous diseases. J Machine Learning Res, 11: 2141-2167, 2010.

 

170.        Przybycin C, Kurman RJ, Ronnett BM, Shih IM, Vang R. Are all pelvic (non-uterine) serous carcinomas of tubal origin? Am J Surg Pathol, 34:1407-1416, 2010. PMID: 20861711

 

171.        Park J, Xu C, Trope CG, Davidson B, Shih IM, Wang TL. Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin. Am J Pathol, 177:1087-1094, 2010. PMID: 20671266

 

172.        Shih IM, Chen L, Wang CC, Gu J, Davidson B, Cope L, Kurman RJ, Xuan J, Wang TL. Distinct DNA methylation profiles in ovarian serous neoplasms and their implications in ovarian carcinogenesis. Am J Ob Gyn, 2010 203:584, e1-e22. PMID: 20965493

 

173.        Davidson B, Reich R, Trope CG, Wang, TL, Shih IM. New determinates of disease progression and outcome in metastatic ovarian carcinoma. Histology and Histopapthology, 25:1591-1609, 2010. PMID:20886439

 

174.        Chen X, Stoeck A, Lee SJ, Shih IM, Wang MM, Wang TL. Jagged1 expression regulated by Notch3 and Wnt/-catenin signaling pathways in ovarian cancer. Oncotarget, 1:210-218, 2010. PMID: 20953350

 

175.        Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, Senz J, McConechy M, Anglesio MS, Kalloger SE, Yang W, Heravi-Moussavi A, Giuliany R, Chow C, Fee J, Zayed A, Melnyk N, Turashvili G, Delaney A, Madore J, Yip S, McPherson AW, Ha G, Bell L, Fereday S, Tam A, Galletta L, Tonin PN, Provencher D, Miller D, Jones S, Moore RA, Morin GB, Oloumi A, Boyd N, Aparicio SA, Shih IM, Mes-Masson A, Bowtell D, Hirst M,  Gilks B, Marra MA, Huntsman DG.  ARID1A gene mutations in endometriosis associated ovarian carcinomas. New Engl J Med, 363:1532-1543, 2010. PMID: 20942669.

 

176.        Jones S, Wang TL, Shih IM, Mao TL, Nakayama K, Roden R, Glas R, Slamon D, Diaz L, Vogelstein B,, Kinzler KW, Velculescu VE,  Papadopoulos N. Exomic sequences of ovarian clear cell carcinomas. Science, 330:228-231, 2010. PMID: 20826764

 

177.        Sheu JJ, Guan B, Choi JH, Lin A, Lee CH, Hsiao YI, Wang TL, Tsai FJ. Shih IM. Rsf-1, a chromatin remodeling protein, induces DNA damage and promotes genomic instability. J Biol Chem, 285:38260-38269, 2010. PMID: 20923775

 

178.        Maeda D, Mao TL, Fukayama M, Yano T, Taketani Y, Nakagawa S, Shih IM. Clinicopathological significance of loss of ARID1A immunoreactivity in ovarian clear cell carcinoma. Int J Mol Sci, 11:5120-5128, 2010.

 

179.        Yu G, Li H, Xuan J, Ha S, Shih IM, Clarke R, Hoffman EP, Madhavan S, Xuan J, Wang Y. PUGSVM: a caBIGTM analytical tool for multiclass gene selection and predictive classification. Bioinformatics, 27:736-738, 2010. PMID: 21186245

 

180.        Davidson B, Stavnes HT, Holth A, Chen X, Yang Y, Shih IM, Wang TL. Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from breast carcinoma in effusions. J Cell Mol Med, 15:535-544, 2011. PMID: 20132413

 

181.        Maeda D, Xu C, Wang TL, Shih IM. Rsf-1 (HBXAP) expression is associated with advanced stage and lymph node metastasis in ovarian clear cell carcinoma. Int J Gyn Pathol, 30:30-35, 2011. PMID: 21131837

 

182.        Olson M, Gocke C, Giuntoli R, Shih IM. Evolution of a trophoblastic tumor from an endometrioid carcinoma- a morphological and molecular analysis. Int J Gyn Pathol, 30:117-120, 2011. PMID:21293290

 

183.        Davidson B, Holth A, Moripen L, Trope CG, Wang TL, Shih IM. Osteopontin expression in ovarian carcinoma effusions is related to improved clinical outcome. Hum Pathol, 42:991-997, 2011. PMID:21315424

 

184.        Shih IM. Trophoblastic vasculogenic mimicry in gestational choriocarcinoma. Mod Pathol, 24:646-652, 2011. PMID: 21217646

 

185.        Wu PH, Hung SH, Ren C, Shih IM, Tseng Y. Cell cycle dependent alteration in NAC1 nuclear body dynamics and morphology. Phys Biol, 8:015005, 2011. PMID:21301057

 

186.        Shih IM, Nakayama K, Wu G, Nakayama N, Zhang J, Wang TL. Amplification of the ch19p13.2 NACC1 locus in ovarian high-grade serous carcinoma. Mod Pathol, 24:638-645, 2011. PMID: 21240255

 

187.        Shih IM, Panuganti PK, Kuo KT, Mao TL, Kuhn E, Jones J, Velculescu VE, Kurman R, Wang TL. Somatic mutations of PPP2R1A in ovarian and uterine carcinomas. Am J Pathol, 178: 1442-1447, 2011. PMID: 21435433

 

188.        Kuhn, E, Meeker A, Visvanathan K, Gross AL, Wang TL, Kurman RJ, Shih IM. Telomere length in different histologic types of epithelial ovarian cancer with emphasis on clear cell carcinoma. Mod Pathol, 24:1139-1145, 2011. PMID: 21499239

 

189.        Guan B, Mao TL, Panuganti PK, Kuhn E, Kurman RJ, Maeda D, Chen E., Jeng YM, Wang TL, Shih IM. Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma. Am J Surg Pathol, 35:625-632, 2011. PMID: 21412130

 

190.        Fang FM, Li CF, Huang HY, Lai MT, Chen CM, Chiu IW, Wang TL, Tsai FJ, Shih IM, Sheu JJ. Overexpression of a chromatin remodeling factor, Rsf-1/HBXAP, correlates with aggressive oral squamous cell carcinoma. Am J Pathol, 178:2407-2415, 2011. PMID: 21514451 (corresponding author)

 

191.        Shih IM, Wang TL. Commentary: Mutation in PPP2R1A- a new clue in unveiling the  pathogenesis of uterine serous carcinoma. J Pathol, 223:567-573, 2011. PMID: 21432855

 

192.        Zhang B, Tian Y, Jin L, Li H, Shih IM, Madhavan S, Clarke R, Hoffman EP, Xuan J, Hilakivi-Clarke L, Wang Y. DDN: A caBIG(R) analytical tool for differential network analysis. Bioinformatics, 27:1036-1038, 2011. PMID:21296752

 

193.        Kurman RJ, Shih IM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer: Shifting the paradigm. Hum Pathol, 42:918-931, 2011. PMID: 21683865

 

194.        Yemelyanova A, Vang R, Morgan MA, Kshirsagar M, Lu D, Shih IM, Kurman RJ. Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma. An immunohistochemical and nucleotide sequencing analysis. Mod Pathol, 24:1248-1253, 2011. PMID: 21552211

 

195.        Yu G, Zhang B, Bova SG, Xu J, Shih IM, Wang Y. BACOM: In silico detection of genomic deletion types and correlation of normal cell contamination in copy number data. Bioinormatics, 27:1473-1480, 2011. PMID: 21498400

 

196.        Lu D, Kuhn E, Bristow RE, Giuntoli RL 2nd, Kjaer SK, Shih IM, Roden RB. Comparison of candidate serologic markers for thye I and type II ovarian cancer. Gyn Oncol, 122:560-566, 2011. PMID: 21704359

 

197.        Guan B, Wang TL, Shih IM. The tumor suppressor role of ARID1A in gynecological cancer. Cancer Res, 71:6718-6727, 2011. PMID: 21900401

 

198.        Kurman RJ, Vang R, Jung J, Hannibal CG, Kjaer SK, Shih IM. Papillary tubal hyperplasia: the putative precursor of ovarian atypical proliferative (borderline) serous tumors, noninvasive implants, and endosalpingiosis. Am J Surg Pathol, 35:1605-1614, 2011. PMID: 21997682

 

199.        Visvanathan K, Vang R, Shaw P, Gross A, Soslow R, Parkash V, Shih IM, Kurman RJ. Diagnosis of serous tubal intraepithelial carcinoma (STIC) based on morphologic and immunohistochemical features- a reproducibility study. Am J Surg Pathol, 35:1766-1775, 2011. PMID:21989347

 

200.        Davidson B, Stavnes HT, Nesland JM, Wohlschlager J, Yang Y, Shih IM, Wang TL. Gene expression signatures differentiate adenocarcinoma of lung and breast origin in effusions. Human Pathol, 43:684-694, 2012. PMID:21937081

 

201.        Kshirsagar M, Jiang W, Shih IM. DNA damage response is prominent in ovarian high-grade serous carcinomas, especially those with Rsf-1 (HBXAP) overexpression. J Oncol, 2012:621685, 2012. PMID:22028712

 

202.        Heaphy CM, Subhawong AP, Jong SM, Goggins MG, Montgomery EA, Gabrielson E, Netto GJ, Epstein JI, Lotan TL, Westra WH, Shih IM, Iacobuzio-Donahue CA, MaitraA, Li QK, Eberhart CG, Taube JM, Rakheja D, Kurman RJ, Wu, TC, Roden R, Argani, P, De Marzo AM, Terracciano L, Torbenson, M, Meeker AK. Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol, 179:1608-1615, 2011. PMID:21888887

 

203.        Jones S*, Wang TL*, Kurman RJ, Nakayama K, Velculescu VE, Vogelstein B, Kinzler KW, Papadopoulos N, Shih IM. Low-grade serous carcinomas of the ovary contain very few point mutations. J Pathol, 226:413-420, 2012. PMID:22102435 (with cover illustration)

 

204.        Kuhn E, Kurman RJ, Vang R, Sehdev AS, Han G, Soslow R, Wang TL, Shih IM. TP53 mutations in serous tubal intraepithelial carcinoma (STIC) and concurrent pelvic high-grade serous carcinoma- evidence supporting their clonal relationship. J Pathol, 226:421-426, 2012.  PMID:21990067

 

205.       Zhang Y, Cheng Y, Ren X, Zhang L, Yap KL, Wu H, Patel R, Liu D, Qin ZH, Shih IM, Yang JM. NAC1 modulates sensitivity of ovarian cancer cells to cisplatin via altering the HMGB1-mediated autophagic response. Oncogene, 31:1055-1064, 2012. (co-corresponding author) PMID:21743489

 

206.        Wu CH, Mao TL, Vang R, Ayhan A, Wang TL, Kurman RJ, Shih IM. Endocervical-type mucinous borderline tumors are related to endometrioid tumors based on mutation and koss of expression of ARID1A. Int J Gyn Pathol, 31:297-303, 2012. PMID: 22653341

 

207.        Vang R, Visvanathan K, Gross A, Maambo E, Gupta M, Kuhn E, Fanghong L, Ronnett BM, Seidman JD, Yemelyanova a, Shih IM, Shaw PA, Soslow RA, Kurman RJ. Validation of an algorithm for the diagnosis of serous tubal intraepithelial carcinoma. Int J Gyn Pathol, 31:243-253, 2012. PMID:22498942

 

208.        Sheu JJC, Guan b, Tsai FJ, Hsia YT, Chen CM, Wang TL, Shih IM. Mutant BRAF induces DNA strand breaks, activates DNA damage response pathway and upregulates glucose transporter-1 in non-transformed epithelial cells. Am J Pathol, 180:1179-1188, 2012. PMID: 22227015

 

209.        Kuhn E, Kurman RJ, Sehdev AS, Shih IM. Ki-67 Labeling Index as an Adjunct in the Diagnosis of Serous Tubal Intraepithelial Carcinoma. Int J Gyn Pathol, 31:416-422, 2012. PMID:22833080

 

210.        Kuhn E, Kurman RJ, Shih IM. Ovarian cancer is an imported disease- fact or fiction? Current Ob Gyn Report, 1:1-9, 2012. PMID: 22506137

 

211.        Zhang Y, Liu K, Wang TL, Shih IM, Wang TH. Mapping DNA quality into electrophoretic mobility through quantum dot nanotethers for high resolution genetic and epigenetic analysis. ACS Nano, 6:858-864, 2012. PMID: 221366000

 

212.        Rahman MT, Nakayama K, Rahman M, Nakayama N, Ishikawa M, Katagiri A, Lida K, Nakayama S, Otsuki Y, Shih IM, Miyazaki K. Prognostic and therapeutic impact of the chromosome 20q13.2 ZNF217 locus amplification in ovarian clear cell carcinoma. Cancer, 118:2846-2857, 2012. PMID:22139760

 

213.          Chen X, Gao M, Xuan J, Chen L, Thiaville M, Stoeck A, Shih IM, Wang TL. Definition of NOTCH3 target genes in ovarian cancers. Cancer Res, 2012; 72 2294-2303. PMID: 22396495

 

214.        Thiaville, M, Stoeck A, Chen L, Wu RC, Magnani L, Oidtman J, Shih IM, Lupien M, Wang TL. Identification of PBX1 target genes in cancer cells by global mapping of PBX1 binding sites. PLoS ONE, e36054, 2012. PMID:22567123

 

215.        Yap KL, Fraley SI, Thiaville MM, Jinawath N, Nakayama K, Wang J, Wang TL, Wirtz D, Shih IM. NAC1 is an actin-binding protein that is essential for effective cytokinesis in cancer cells. Cancer Res, 72:4085-4096, 2012. PMID:22761335

 

216.       Zhang Y, Cheng Y, Ren X, Hori T, Huber-Keener K, Zhang L, Yap KL, Liu D, Shantz LM, Qin ZH, Zhang S, Wang J, Wang HG, Shih IM, Yang JM. Dysfunction of nucleus accumbens-1 (NAC1) activates cellular senescence and inhibits tumor cell proliferation and oncogenesis. Cancer Res, 72:4265-4275, 2012. PMID:22665267

 

217.        Kuhn E, Wu RC, Wu G, Guan B, Zhang J, Wang Y, Song L, Yuan X, Wei L, Roden RBS, Kuo KT, Nakayama K, Clarke B, Shaw P, Olvera N, Levine DA, Kurman RJ, Wang TL, Shih IM. Genome-wide analyses of uterine serous carcinoma identify pathway aberrations involving cyclin E-Fbxw7, PI3K and p53. J Natl Cancer Inst, 104:1503-1513, 2012. PMID:22923510

 

218.          Kuhn E, Kurman RJ, Soslow R, Sehdev AS, Morin PJ, Wang TL, Shih IM. The diagnostic and biological implications of laminin expression in serous tubal intraepithelial carcinoma. Am J Surg Pathol, 36:1826-1834, 2012. PMID:22892598

 

219.       Wang C, Xuan J, Shih IM, Clarke R, Wang Y. Regulatory component analysis: a semi-blind extraction approach to infer gene regulatory networks with imperfect biological knowledge. Signal Processing, 92:1902-1915, 2012. PMID:22685363

 

220.       Rahman M, Nakayama K, Rahman MT, Nakayama N, Ishikawa M, Katagiri A, Iida K, Nakayama S, Otsuki Y, Shih IM, Miyazaki K. Clinicopathological and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma. Hum Pathol, 43:2197-2206, 2012. PMID: 22705003

 

221.       Yeh HC, Sharma J, Shih IM, Vu D, Martinez J, Werner J. A flouresence ligh-up Ag nanocluster probe that discriminates single-nucleotide variants by emission color. J Am Chem Society. 134:11550-11558, 2012. PMID: 22775452

 

222.       Ayhan A, Mao TL, Seckin T, Wu CH, Guan B, Ogawa H, Futagami M, Mizukami H, Yokoyama Y, Kurman RJ, Shih IM. Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma. Int J Gyn Cancer. 22:1310-1315, 2012. PMID:22976498

 

223.       Yuan X, Yu G, Hou X, Shih IM, Clarke R, Zhang J, Hoffman EP, Wang RR, Zhang Z, Wang Y. Genome-wide identification of significant aberrations in cancer genome. BMC Genomics, 13:342, 2012. PMID:22839576

 

224.       Yap KL, Shih IM. NACC1 (nucleus accumbens associated 1, BEN and BTB (POZ) domain containing). Atlas Genet Cytogenet Oncol Haematol, 16:723-726, 2012.

 

225.       Shih IM, Ho CM, Nakayama K, Salani R. Pathogenesis and new therapeutic targets of ovarian cancer. J Oncol, 2012:867512, 2012. PMID:22969800

 

226.       Guan B, Gao M, Wu CS, Wang TL, Shih IM. Functional analysis of in-frame indel ARID1A mutations reveals new regulatory mechanisms of its tumor suppressor functions. Neoplasia, 14:986-993, 2012. PMID:23097632

 

227.       Yang YI, Lee KT, Park HJ, Kim TJ, Choi YS, Shih IM, Choi JH. Tectorigenin sensitize paclitaxel-resistant human ovarian cancer cells through downregulation of the Akt and NFB pathway. Carcinogenesis, 33:2488-2498, 2012. PMID:23027625.

 

228.       Gao M, Shih IM, Wang TL. The role of Forkhead Box Q1 transcription factor in ovarian epithelial carcinomas. Int J Mol Sci, 13:13881-13893, 2012. PMID:23203039

 

229.       Sheu J, Choi JH, Guan B, Tsai FJ, Hua CH, Lai MT, Wang TL, Shih IM. Rsf-1, a chromatin remodeling protein, interacts with cyclin E1 and promotes tumor development. J Pathol, 229:559-568, 2013. PMID:23378270

 

230.       Davidson B, Abeler VM, Hellesylt E, Hoth A, Shih IM, Skele-Jensen, Chen L, Yang Y, Wang TL. Gene expression signatures differentiate uterine endometrial stromal sarcoma from leiomyosarcoma. Gyn Oncol, 128:349-355, 2013. PMID:23181618

 

231.       Cope L, Wu, RC, Shih IM, Wang TL. High level of chromosomal aberration in ovarian cancer genome correlates with poor clinical outcome. Gyn Oncol, 128:500-505, 2013. PMID:23200914

 

232.       Maeda D, Shih IM. Pathogenesis and the role of ARID1A mutation in endometriosis-related ovarian neoplasms. Adv Anatomic Pathol, 20:45-52, 2013. PMID:23232571

 

233.       Marzinke MA, Choi CH, Chen L, Shih IM, Chan DW, Zhang H. Proteomic analysis of temporally stimulated ovarian cancer cells for biomarker discovery. Mol Cell Proteom, 12:356-368, 2013. PMID:23172893

 

234.       Hromatka BS, Drake PM, Kapidzic m, Stolp H, Goldfien GA, Shih IM, Fisher SJ. Polysialic acid enhances the migration and invastion of human cytotrophoblast. Glycobiology, 23:593-602, 2013. PMID:23208007

 

235.       Vang R, Shih IM, Kurman RJ. Fallopian tube precursors of ovarian low- and high-grade serous neoplasms. Histopathology, 62:44-58, 2013. PMID:23240669

 

236.       Kinde I, Bettegowda C, Wang Y, Wu J, Agrawal N, Shih IM, Kurman RJ, Dao F, Levine DA, Giuntoli R, Roden R, Eshleman FR, Carvalho JP, Marie SKN, Papadopoulos N, Kinzler KW, Vogelstein B, Diaz LA. Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med, 5:167ra4, 2013. PMID:23303603

 

237.       Mao TL, Ardighieri L, Ayhan A, Kuo KT, Wang TL, Shih IM. Loss of ARID1A expression correlates with stages of tumor progression in uterine endometrioid carcinoma. Am J Surg Pathol, 37:1342-1348, 2013. PMID:24076775

 

238.       Zheng G, Martignoni G, Antonescu C, Montgomery E, Eberhart C, Netto G, Taube J, Westra W, Epstein J, Lotan T, Maitra A, Gabrielson E, Torbeson M, Iacobuzio-Donahue, Dermazo A, Shih IM, Ellei P, Wu TC, Argani P. A broad survey of cathepsin K immunoreactivity in human neoplasms. Am J Clin Pathol, 139:151-9, 2013. PMID:23355199

 

239.       Wu E, Shih IM, Diaz-Montes TP. Dedifferentiated endometrioid adenocarcinoma: an under-recognized but aggressive tumor? Gynecol Oncol Case Rep, 5:25-27, 2013. PMID: 24371688

 

240.       Kushnir CL, Gerardi M, Banet N, Shih IM, Diaz-Montes T. Extrauterine inflammatory myofibroblastic tumor: A case report. Gynecol Oncol Case Rep, 6:39-41, 2013. PMID: 24371717

 

241.       Killela PJ, Ritman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA, Friedman A, Gallia G, Giovanella BC, Grollman AP, He TC, He Y, Hruban RH, Jallo GI, Meeker AK, Mertens F, Netto G, Rasheed A, Rosenquist T, Schiffman M, Shih IM, Theodorescu D, Torbenson MS, Velculescu VE, Wang TL, Wentzensen N, Wood LD, Zhang M, McLendon RE, Bigner DD, Papadopoulos N, Kinzer KW, Vogelstein B, Yan H. TERT promoter mutations occur frequently in gliomas and in a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci USA, 110:6021-6026, 2013. PMID:23530248

 

242.       Kurman RJ, Visvanathan K, Shih IM. Bokhman’s dualistic model of endometrial carcinoma- revisited. Gyn Oncol, 129:271-272, 2013. PMID:23582581

 

243.       Yap KL, Shah PS, Bolon B, Wu RC, Gao M, Wang F, Faiola F, Huso D, Wang TL, Wang JL, Shih IM. Loss of NAC1 expression is associated with defective cell fate specification and bony patterning in the murine vertebral axis. PLoS one, 8:e69099, 2013. PMID:23922682

 

244.       Guan B, Mogami T, Wang TL, Shih IM. Establishing isogenic inducible cell lines using founder reporter lines and recombinase-mediated cassette exchange. Biotechniques, 55:233-242, 2013. PMID:24215638

 

245.       Kuhn E, Ayhan A, Shih IM, Seidman JD, Kurman RJ. The pathogenesis of atypical proliferative Brenner tumor: an immunohistochemical and molecular genetic analysis. Mod Pathol, 2013, PMID: 23887305

 

246.       Mao TL, Shih IM. The roles of ARID1A in gynecological cancer. J Gyn Oncol, 24:376-381, 2013. PMID:24167674

 

247.       Kuhn E, Seidman J, Ayhan A, Shih IM, Kurman RJ. Ovarian Brenner tumor: a morphologic and immunohistochemical analysis suggesting an origin from fallopian tube epithelium. Eur J Cancer, 49:3839-3849, 2013. PMID:24012099

 

248.       Allo G, Bernardini MQ, Wu RC, Shih IM, Kalloger S, Pollett A, Gilks CB, Clarke BA. ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas. Mod Pathol, 27: 255-261, 2014. PMID:23887303

 

249.       Nik NN, Vang R, Shih IM, Kurman RJ. Origin and pathogenesis of pelvic (ovarian, tubal and primary peritoneal) serous carcinoma. Ann Rev Pathol, 9:27-45, 2014. PMID:23937438

 

250.       Gao M, Uw RC, Herlinger AL, Yap K, Kim JW, Wang TL, Shih IM. Identification of NAC1-regulated genes in ovarian cancer. Am J Pathol, 184:133-140, 2014. PMID:24200849

 

251.       Ardighieri L, Lonardi S, Moratto D, Facchetti F, Shih IM, Vermi W, Kurman RJ. Characterization of the immune cell repertoire in the normal fallopian tube- implications for understanding ovarian carcinogenesis. Int J Gyn Cancer, 33:581-591, 2014. PMID: 25172297

 

252.       Kuhn E, Bahadirli A, Shih IM. Frequent CCNE1 amplification in endometrial intraepithelial carcinoma and uterine serous carcinoma. Mod Pathol, 27:1014-1019, 2014. PMID:24309323.

 

253.       Ardighieri L, Zeppernick F, Hannibal CG, Vang R, Cope L, Junge J, Kjaer SK, Kurman RJ, Shih IM. Mutational analysis of BRAF and KRAS in ovarian atypical proliferative serous (borderline) tumors and associated peritoneal implants. J Pathol, 232:16-22, 2014.  PMID:24307542

 

254.       Wu RC, Syhan A, Maeda D, Kim KR, Clarke BA, Shaw P, Chiu MH, Rosen B, Shih IM, Wang TL. Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynecologic malignancies. J Pathol, 232:473-481, 2014. PMID:24338723. (corresponding author)

 

255.       Kuhn E, Ayhan A, Bahadirli-Talbott, Zhao Chengquan, Shih IM. Molecular characterization of undifferentiated carcinoma associated with endometrioid carcinoma. Am J Surg Pathol, 38:660-665, 2014. PMID:24451280

 

256.       Maniar KP, Wang YH, Visvanathan K, Shih IM, Kurman RJ. Evaluation of microinvastion and lymph node involvement in ovarian borderline/atypical proliferative serous tumors. A morphologic and immunohistochemical analysis of 37 cases. Am J Surg Pathol, 38:743-755, 2014. PMID:24441661

 

257.       Zhang B, Hou X, Yuan X, Shih IM, Zhang Z, Clarke R, Wang RR, Fu Y, Madhavan S, Wang Y, Yu G. AISAIC, a software suite for accurate identification of significant aberrations in cancers. Bioinformatics, 30:431-433, 2014. PMID:24292941

 

258.       Davidson B, Abeler VM, Forsund M, Holth A, Yang Y, Kobayshi Y, Chen L, Kristensin GB, Shih IM, Wang TL. Gene expression signatures of primary and metastatic uterine leiomyosarcoma. Hum Pathol, 45:691-700, 2014. PMID:24485798

 

259.       Yang YI, Ahn JH, Lee KT, Shih IM, Choi JH. RSF-1 is a positive regulator of NFB-induced gene expression required for ovarian cancer chemoresistance. Cancer Res, 74:2258-2269, 2014. PMID:24566868

 

260.       Rodic N. Sharma R, Sharma R, Zampella J, Dai L, Taylor MS, Hruban RH, Iacobuzio-Donahue CA, Maitra A, Torbenson MS, Goggins M, Shih IM, Duffield AS, Montgomery EA, Gabrielson E, Netto GJ, Lotan TL, De Marzo AM, Westra W, Binder ZA, Orr BA, Gallia GL, Eberhart CG, Boeke JD, Harris CR, Burns KH. Long interspersed element-1 protein expression is a hallmark of many human cancers. Am J Pathol, 184:1280-1286, 2014. PMID:24607009

 

261.       Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, Antonarakis ES, Azad NS, Bardelli A, Brem H, Cameron JL, Lee CC, Fecher LA, Gallia GL, Gibbs P, Le D, Giuntoli RL, Goggins M, Hogarty MD, Holdhoff M, Hong SM, Jiao Y, Juhl HH, Kim JJ, Siravegna G, Laheru DA, Lauricella C, Lim M, Lipson EJ, Marie SK, Netto GJ, Oliner KS, Olivi A, Olsson L, Riggins GJ, Sartore-Bianchi A, Schmidt K, Shih l M, Oba-Shinjo SM, Siena S, Theodorescu D, Tie J, Harkins TT, Veronese S, Wang TL, Weingart JD, Wolfgang CL, Wood LD, Xing D, Hruban RH, Wu J, Allen PJ, Schmidt CM, Choti MA, Velculescu VE, Kinzler KW, Vogelstein B, Papadopoulos N, Diaz LA, Jr.: Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 2014, 6:224ra24. PMID:24553385

 

262.       Wu RC, Wang TL, Shih IM. The emerging roles of ARID1A in tumor suppression. Cancer Biol Ther, 15:655-664, 2014. PMID:24618703

 

263.       Kurman RJ, Shih IM. Discovery of a cell: reflections on the checkered history of intermediate trophoblast and update on its nature and pathologic manifestations. Int J Gyn Pathol, 33:339-347, 2014. PMID:24901393

 

264.       Tian Y, Wang SS, Zhang Z, Rodriguez OC, Petricoin E 3rd, Shih IM, Chan D, Avantaggiati M, Yu G, Ye S, Clarke R, Wang C, Zhang B, Wang Y, Albanese C. Integration of network biology and imaging to study cancer phenotypes and responses. IEEE/ACM Trans Comput Biol Bioinform, 11:1009-1019, 2014.

 

265.       Sherman-Baust C, Kuhn E, Valle BL, Shih IM, Kurman RJ, Wang TL, Amano T, Ko MSH, Miyoshi I, Araki Y, Lehrmann E, Zhang Y, Becker DG, Morin PJ. A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development. J Pathol, 233:228-237, 2014. PMID: 24652535

 

266.       Guan B, Rahmanto YS, Wu RC, Wang Y, Wang Z, Wang TL, Shih IM. The roles of deletion of Arid1a, a tumor suppressor, in mouse ovarian tumorigenesis. J Natl Cancer Inst, June 4; 106(7). doi: 10.1093/jnci/dju146 (July issue). 2014. PMID:24899687

 

267.       Zeppernick F. Ardigheri L, Hannibal CG, Vang R, Junge J, Kjaer SK, Zhang R, Kurman RJ, Shih IM. BRAF mutation is associated with a specific cell-type with features suggestive of senescence in ovarian serous borderline (atypical proliferative) tumors. Am J Surg Pathol, 38:1603-1611, 2014. PMID: 25188864

 

268.       Faraj SF, Chaux A, Gonzale-Roibon N, Munari E, Ellis C, Driscoll T, Schoenberg MP, Bivalacqua TJ, Shih IM, Netto GJ. ARID1A immunohistochemistry improves outcome prediction in invasive urothelial carcinoma of urinary bladder. Hum Pathol, 45:2233-2239, 2014. PMID:25175170

 

269.       Jung J, Stoeck A, Guan B, Wu RC, Zhu H, Blackshaw S, Shih IM, Wang TL. Notch3 interactome analysis identified WWP2 as a negative regulator of Notch3 signaling in ovarian cancer. PLoS Genetics, 10:e1004751, 2014. PMID:25356737

 

270.       Tian Y, Zhang B, Hoffman EP, Clarke R, Zhang Z, Shih IM, Xuan J, Herrington DM, Wang Y. KDDN: An open-soruce cytoscape app for constructing differential dependency networks with significant rewiring. Bioinformatics, 31:287-289, 2015, PMID: 25273109

 

271.       Zhang B, Wang J, Wang X, Zhu J, Liu Q, Shi Z, Chambers MC, Zimmerman LJ, Shaddox KF, Kim S, Davies SR, Wang S, Wang P, Kinsinger CR, Rivers RC, Rodriguez H, Townsend RR, Ellis MJ, Carr SA, Tabb DL, Coffey RJ, Slebos RJ, Liebler DC, and NCI CTPAC: Proteogenomic characterization of human colon and rectal cancer. Nature 2014.

 

272.       Tian Y, Zhang B, Hoffman E, Clarke R, Zhang Z, Shih IM, Xuan J, Herrington D, Wang Y. Knowledge-fused differential dependency network models for detecting significant rewiring in biological networks. BMC Syst Biol, 8:87, doi: 10.1186/s12918-014-0087-1, 2014.

 

273.       Banet N. Gown AM, Shih IM, Kay LQ, Roden RB, Nucci MR, Cheng L, Przybycin CG, Nasseri-Nik N, Wu LS, Netto GJ, Ronnett BM, Vang R. GATA-3 epxression in trophoblastic tissues: an immunohistochemical study of 445 cases, including diagnostic utility.  Am J Surg Pathol, 39:101-108, 2015. PMID: 25188865

 

274.       Zeppernick F, Meinhold-Heerlein I, Shih IM. Precursors of ovarian cancer in the tube- STIC an update. J Obstet Gynaecol Res, 41:6-11, 2015. PMID: 25330822

 

275.       Wang N, Gong T, Clarke R, Chen L, Shih IM, Zhang Z, Levine DA, Xuan J, Wang Y. UNDO: a Bioconductor R package for unsupervised deconvolution of mixed gene expressions in tumor samples. Bioinformatics, 31:137-139, 2015. PMID: 25212756

 

276.       Chui MH, Wang Y, Wu RC, Seidman J, Kurman RJ, Wang TL, Shih IM. Loss of ALDH1A1 expression is an early event in the pathogenesis of ovarian high-grade serous carcinoma. Mod Pathol, 28:437-445, 2015. PMID: 25216223

 

277.       Lai TH, Vlahos N, Shih I, Zhao Y. Expression of VEGF and Flk-1 in human endometrium at the various phases of the normal menstrual cycle. J Reprod Infertil, 16: 3-9, 2015. PMID: 25717429

 

278.       Bitler BG, Aird KM, Garipov A, Li H, Amatangelo M, Kossenkov AV, Schultz DC, Liu Q, Shih IM, Conefo-Garcia JR, Speicher DW, Zhang R. Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. Nat Med, 21:231-238, 2015. PMID:25686104

 

279.       Faraj SF, Chaux A, Gonzalez-Roibon N, Munari E, Cubilla AL, Shih IM, Netto GJ. Immunohistochemical expression of ARID1A in penile squamous cell carcinomas: a tissue microarray study of 112 cases. Hum Pathol, 46:761-766, 2015. PMID: 25776029

 

280.       Ayhan A, Mao TL, Rahmanto YS, Ogawa H, Wu RC, Wang TL, Shih IM. Increased proliferation in atypical hyperplasia/endometrioid intraepithelial neoplasia of endometrium with concurrent inactivation of ARID1A and PTEN tumor suppressors. J Pathol Clin Res, 1:186-193, 2015. PMID: 27499903

 

281.       Ju J, Kapoor P, Shen X, Shih IM,  Peng G. ARID1A deficiency impairs the DNA damage checkpoint and sensitizes cells to PARP inhibitors. Cancer Discovery, 5:752-767, 2015. PMID: 26096845

 

282.       Yu Y, Gaillard S, Jude MP, Huang TC, Pinto SM, Tessarollo NG, Zhang Z, Pandey A, Wirtz D, Ayhan A, Davidson B, Wang TL, Shih IM.  Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules. Cancer Cell, 28:82-96, 2015. PMID: 26096845

 

283.       Kobayashi Y, Kashima H, Wu RC, Jung J, Kuan JC, Gu J, Xuan J, Visvanathan K, Shih IM, Wang TL. Mevalonate pathway antagonist inhibits proliferation of serous tubal intraepithelial carcinoma and ovarian carcinoma in mouse models. Clin Cancer Res, 21:4652-62, 2015. PMID: 26109099

 

284.       Wang YH, Wu RC, Shwartz LE, Haley L, Lin MT, Shih IM, Kurman RJ. Clonality analysis of combined Brenner and mucinous tumours of the ovary reveals their monoclonal origin. J Pathol, 237:146-151, 2015. PMID: 26095692

 

 

285.       Wang YH, Anderson D, Haley L, Lin MT, Shih IM, Kurman RJ. Molecular analysis of ovarian mucinous carcinoma reveals different cell of origins. Oncotarget, 6:22949-58, 2015. PMID: 26355245

 

286.       Cobb LP, Gaillard S, Wang YH, Shih IM, Secord AA. Adenocarcinoma of Mullerian origin: review of pathogenesis, molecular biology, and emerging treatment paradigms. Gyn Oncol Res Pract, 2:1, 2015.

 

287.       Fu Y, Yu G, Levine D, Wang N, Shih IM, Zhang Z, Clarke R, Wang Y. BACOM2.0 facilitates absolute normalization and quantification of somatic copy number alterations in heterogeneous tumor. Scientific Reports, 5:13955, 2015. PMID:26350498

 

288.       Kashima H, Wu RC, Wang Y, Sinno A, Miyamoto T, Shiozawa T, Wang TL, Fader AN, Shih IM. Laminin C1 expression by uterine carcinoma cells is associated with tumor progression. Gyn Oncol, 139:338-344, 2015. PMID: 26343160

 

289.       Gerry E, Shih IM. Will shorter time interval to diagnose ovarian cancer improve early detection? A perspective from the dualistic model. Br J Ob Gyn, 123:1021, 2016. PMID: 26138012

 

 

290.       Vang R, Levine DA, Soslow RA, Zaloudek C, Shih IM, Kurman RJ. Molecular alterations of TP53 are a defining feature of ovarian high-grade serous carcinoma: A re-review of cases lacking TP53 mutations in The Cancer Genome Atlas Ovarian study. Int J Gynecol Pathol, 35:48-55, 2016. PMID:26166714

 

291.       Kurman RJ, Shih IM. Seromucinous Tumors of the Ovary. What's in a Name? Int J Gyn Pathol, 35:78-81, 2016. PMID: 26598986

 

292.       Kurman RJ, Shih IM. The Dualistic Model of Ovarian Carcinogenesis. Revisited, Revised and Expanded.  Am J Pathol, 186:733-747, 2016. PMID: 27012190

 

293.       Chen X. Jung JG, Shajahan-Haq AN, Clarke R, Shih IM, Wang Y, Magnani L, Wang TL, Xuan J. ChIP-BIT Bayesian inferences of target genes using a novel joint probabilistic model of ChIP-seq profiles. Nucleic Acids Res, 44:e65, 2016. PMID:  26704972

 

294.       Rahmanto YS, Jung JG, Wu RC, Kobayashi Y, Heaphy CM, Meeker AK, Wang TL, Shih IM. Inactivating ARID1A tumor suppressor enhances hTERT transcription and maintains telomere length in cancer cells. J Biol Chem, 291:9690-9699, 2016. PMID: 26953344

 

295.       Kito M, Maeda D, Kudo-Asabe Y, Sato N, Shih IM, Wang TL, Tanaka M, Terada Y. Goto A. Expression of cell competition markers at the interface between p53 signature and normal epithelium in the human fallopian tube. PLoS One, 11(6):e0156069, 2016. PMID: 27258067

 

296.       Kuhn E, Wang TL, Doberstein K, Bahadirli-Talbott A, Ayhan A, Sehdev S, Drapkin R, Kurman RJ, Shih IM. CCNE1 amplification and centrosome number abnormality in serous tubal intraepithelial carcinoma- further evidence supporting its role as a precursor of ovarian high-grade serous carcinoma. Mod Pathol, 29:1254-1261, 2016. PMID:27443516

 

297.       Sherman ME, Drapkin RI, Horowitz NS, Crum CP, Friedman S, Kwon J, Levine DA, Shih IM, Shoupe D, Swisher EM, Walker J, Trabert B, Greene MH, Samimi G, Temkin SM, Minasian LM. Rationale for developing a specimen bank to study the pathogenesis of high-grade serous carcinoma: a review of evidence. Can Prev Res, 9:713-720, 2016. PMID: 27221539

 

 

298.       Wang Y, Sundfeldt K, Mateoiu C, Shih IM, Kurman RJ, Schaeffer J, Silliman A, Kinde I, Springer S, Foote M, Kristjansfottir B, James N, Kinzler KW, Papadopoulos N, Diaz LA, Vogelstein B. Diagnostic potential of tumor DNA from ovarian cyst fluid. Elife, doi: 10.7554/eLife.15175, 2016. PMID: 27421040

 

299.       Zhang, H, Liu T, Zhang Z, Payne SH, Zhang B, McDermott JE, Zhou JY, Petyuk VA, Chen L, Ray D, Sun S, Yang F, Chen L, Wang J, Shah P, Cha SW, Aiyetan P, Woo S, Tian Y, Gritsenko MA, Nie S, Uw C, Moore RJ, Yu KH, Tabb DL, Genyo D, Bafna V, Wang Y, Rodriguez H, Boja E, Hiltke T, Rivers RC, Sololl L, Zhu H, Shih IM, Cope L, Pandey A, Zhang B, Snyder, MP, Levine DA, Smith R, Chan DW, Rodland KD and CPTAC investigators. Integrated proteogenomic characterization of human high grade serous ovarian cancer. Cell, 166:755-765, 2016. PMID: 27372738

 

300.       Youssef I, Clarke R, Shih IM, Wang Y, Yu G. Biologically inspired survival analysis based on integrating gene expression as mediator with genomic variants. Comput Bio Med, 77:231-239, 2016. PMID: 27619193

 

301.       Jung JG, Shih IM, Park JT, Gerry E, Kim TH, Ayhan A, Handshuh K, Davidson B, Fader AN, Selleri L, Wang TL. The expression of PBX1, a stem cell reprogramming factor, in ovarian cancer chemoresistance. Cancer Res, 76:6351-6361, 2016. PMID: 27590741

 

 

302.       Veras E, Kurman RJ, Wang TL, Shih IM. PDL-1 expression in human placentas and gestational trophoblastic diseases. Int J Gyn Pathol, 36:146-153, 2017. PMID: 27362903

 

303.       Ayhan A, Kuhn E, Wu RC, Ogawa H, Talbott AB, Mao TL, Sugimura H, Shih IM, Wang TL. CCNE1 copy number gain and overexpression identifies ovarian clear cell carcinoma with a poor prognosis. Mod Path, 30:297-303, 2017. PMID: 27767100

 

304.       Lin SF, Gerry E, Shih IM. Tubal origin of ovarian cancer- the double-edged sword of haemaglobin. J Pathol, 242:3-6, 2017. PMID: 28054715

 

305.       Tang Z, Steranka JP, Ma S, Grivainis M, Rodic N, Huang CR, Shih IM, Wang TL, Boeke JD, Fenyo D, Burns KH. Human transposone insertion profiling: Analysis, visualization and idenfification of somatic LINE-1 insertions in ovarian cancer. Proc Natl Acad Sci USA, 114:E733-E740, 2017. PMID: 28096347

 

306.       Wilbur MA, Shih IM, Segars JH, Fader AN. Cancer implications for patients with endometriosis. Sem Reprod Med, 35:110-116, 2017. PMID: 28049216

 

307.       Angeleso M, Papdopoulos N, Ayhan A, Wang TL, Nazeran TM, Horlings HM, Noe M, Lum A, Jones S, Senz J, Seckin T, Ho J, Wu RC, Lac V, Ogawa H, Tessier-Cloutier B, Alhassan R, Wang A, Wang Y, Cohen, J, Wong F, Hasanovic A, Orr, Wang M, Popoli M, McMahon W, Wood L, Mattox A, Allaire C, Segars J, Williams C, Tomasetti C, Boyd N, Kinzler KW, Gilks B, Diza L, Wang TL, Vogelstein B, Yong PJ, Huntsman DG, Shih IM. Cancer associated mutations in endometriosis without cancer. N Engl J Med, 376:1835-1848, 2017. PMID: 28489996

 

308.       Bergstrom J, Jernigan A, Tanner EJ, Roche KL, Stone RL, Ricci S, Levinson K, Wethington, S, Shih IM, Wang TL, Yang B, Armstrong DK, Zhang G, Gaillard S, Michener C, DeBernardo R, Rose PG, Fader A. Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: reducing overtreatment without compromising survival? Gyn Oncol, 147:85-91, 2017. PMID:28768570

 

309.       Stone ML, Chiappinelli KB, Li H, Murphy LM, Travers ME, Topper M, Mathios D, Lim M, Shih IM, Wang TL, Hung CF, Bhargava V, Wiehagen KR, Cowley GS, Bachman KE, Strick R, Strissel PL, Gaylin SB, Zahnow CA. Combination epigenetic therapy regulates tumor cells and the immune microenvironment to sensitize ovarian cancer to immune checkpoint therapy. Proc Natl Acad Sci, 114: E10981-10990, 2017. PMID: 29203668

 

310.       Ducie J, Dao F, Considine M, Olvera N, Shaw P, Kurman RJ, Shih IM, Soslow RA, Cope L, Levine DA. Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma. Nat Comm, 8:990, 2017. PMID: 29042553

 

311.       Labidi-Galy I, Papp E, Hallberg D, Niknafs N, Adleff V, Now M, Bhattacharya R, Novak M, Jones S, Phallen J, Hurban CA, Hirsch MS, Lin DI, Schwartz L, Maire CL, Tille JC, Bowden M, Ahyan A, Wood LD, Scharpf RB, Kurman RJ, Wang TL, Shih IM, Karchin R, Drapkin R, Velculescu VE. High grade serous ovarian carcinomas originate in the fallopian tube. Nat Comm, 8:1093, 2017. PMID: 29061967

 

312.       Wu RC, Veras E,